GZ402671
Drug
GENZYME CORPORATION
Total Payments
$3.8M
Transactions
1,085
Doctors
28
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $3.5M | 323 | 18 |
| 2018 | $166,839 | 516 | 9 |
| 2017 | $70,217 | 246 | 16 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.7M | 1,006 | 98.2% |
| Consulting Fee | $61,725 | 67 | 1.6% |
| Travel and Lodging | $3,208 | 7 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,093 | 1 | 0.0% |
| Food and Beverage | $130.16 | 4 | 0.0% |
Payments by Type
Research
$3.7M
1,006 transactions
General
$66,156
79 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease | GENZYME CORPORATION | $2.5M | 0 |
| Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at Risk of Rapidly Progres | GENZYME CORPORATION | $588,519 | 0 |
| Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease | SANOFI US SERVICES INC. | $163,081 | 11 |
| A 52-week Two-part, Open-label, Multicenter, Multinational Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Combination With Cerezyme | SANOFI US SERVICES INC. | $154,202 | 0 |
| A 52-week Two-part, Open-label, Multicenter, Multinational Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Combination With Cerezyme | GENZYME CORPORATION | $114,335 | 0 |
| An Open-label, Multicenter, Multinational Extension Study of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Adult Male Patients Diagnosed With Fabry Disease | GENZYME CORPORATION | $35,064 | 0 |
| Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at Risk of Rapidly Progres | SANOFI US SERVICES INC. | $30,503 | 0 |
| An Open-label, Multicenter, Multinational Extension Study of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Adult Male Patients Diagnosed With Fabry Disease | SANOFI US SERVICES INC. | $26,910 | 1 |
| GZ/SAR402671 in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 (LEAP) | GENZYME CORPORATION | $13,594 | 2 |
| A Non-Interventional Study to Assess the Psychometric Properties of a Patient-Reported Outcome (PRO) Instrument in Patients with Fabry Disease (FD) | GENZYME CORPORATION | $5,200 | 0 |
| A Non-Interventional Study to Assess the Psychometric Properties of a Patient-Reported Outcome (PRO) Instrument in Patients with Fabry Disease (FD) | SANOFI US SERVICES INC. | $3,651 | 0 |
| Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-na?ve Adult Male Patients With Fabry Disease | GENZYME CORPORATION | $2,118 | 3 |
| Multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of GZ, SAR402671 in patients with early-stage Parkinson?s disea | GENZYME CORPORATION | $1,330 | 4 |
| Multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of GZ/SAR402671 in patients with early-stage Parkinson's disease | GENZYME CORPORATION | $387.40 | 4 |
| Autosomal Dominant Polycystic Kidney Disease | SANOFI US SERVICES INC. | $243.29 | 0 |
Top Doctors Receiving Payments for GZ402671 — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Eric Wallace | Nephrology | Birmingham, AL | $294.00 | 1 |
| , MBBS PHD | Gastroenterology | New Haven, CT | $265.00 | 1 |
| , M.D | Plastic Surgery | Grand Rapids, MI | $198.39 | 3 |
| , MD | Pediatrics | Minneapolis, MN | $10.74 | 1 |
Ad
Manufacturing Companies
- GENZYME CORPORATION $3.3M
- SANOFI US SERVICES INC. $381,647
- SANOFI-AVENTIS U.S. LLC $61,924
Product Information
- Type Drug
- Total Payments $3.8M
- Total Doctors 28
- Transactions 1,085
About GZ402671
GZ402671 is a drug associated with $3.8M in payments to 28 healthcare providers, recorded across 1,085 transactions in the CMS Open Payments database. The primary manufacturer is GENZYME CORPORATION.
Payment data is available from 2017 to 2019. In 2019, $3.5M was paid across 323 transactions to 18 doctors.
The most common payment nature for GZ402671 is "Unspecified" ($3.7M, 98.2% of total).
GZ402671 is associated with 15 research studies, including "Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease" ($2.5M).